NUTEX HEALTH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.718 USD | +1.13% |
|
+1.13% | -73.41% |
| May. 09 | Earnings Flash (NUTX) NUTEX HEALTH Posts Q1 Revenue $67.5M | MT |
| May. 09 | Nutex Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 1,237 | 120.7 | 36.23 | - |
| Enterprise Value (EV) 1 | 1,237 | 120.7 | 36.23 | 36.23 |
| P/E ratio | -2.84 x | -2.57 x | -3.31 x | -5.61 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 5.64 x | 0.49 x | 0.13 x | 0.11 x |
| EV / Revenue | 5.64 x | 0.49 x | 0.13 x | 0.11 x |
| EV / EBITDA | 98.6 x | 11.2 x | 1.69 x | 1.11 x |
| EV / FCF | 34,389,180 x | - | - | - |
| FCF Yield | 0% | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 43,408 | 44,719 | 49,695 | - |
| Reference price 2 | 28.50 | 2.700 | 0.7291 | 0.7291 |
| Announcement Date | 3/2/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 330.1 | 219.3 | 247.6 | 286.2 | 333.6 |
| EBITDA 1 | - | 12.55 | 10.83 | 21.5 | 32.7 |
| EBIT 1 | - | -4.578 | -1.292 | 9.9 | 14.7 |
| Operating Margin | - | -2.09% | -0.52% | 3.46% | 4.41% |
| Earnings before Tax (EBT) 1 | - | -419.6 | -48.49 | -5 | 0.7 |
| Net income 1 | 132.6 | -424.8 | -45.79 | -10.7 | -6.3 |
| Net margin | 40.17% | -193.7% | -18.49% | -3.74% | -1.89% |
| EPS 2 | - | -10.05 | -1.050 | -0.2200 | -0.1300 |
| Free Cash Flow | - | 35.97 | - | - | - |
| FCF margin | - | 16.4% | - | - | - |
| FCF Conversion (EBITDA) | - | 286.7% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 6/16/22 | 3/2/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 53.72 | 56.33 | 58.92 | 62.72 | 69.67 | 67.45 | 69.7 | 71.7 | 77.4 | 78 |
| EBITDA 1 | - | -5.908 | 2.438 | 3.995 | 1.279 | 3.116 | 4.56 | 6.9 | 4.2 | 5.8 | 7 |
| EBIT 1 | - | -5.779 | -4.228 | -0.3625 | -0.8212 | 4.077 | -1.151 | 3.6 | 1.4 | 3.5 | 2.5 |
| Operating Margin | - | -10.76% | -7.51% | -0.62% | -1.31% | 5.85% | -1.71% | 5.16% | 1.95% | 4.52% | 3.21% |
| Earnings before Tax (EBT) 1 | - | 1.478 | -7.833 | -5.082 | -4.866 | -30.71 | -0.1528 | 0.1 | -2.1 | - | -1 |
| Net income 1 | -422.5 | -4.421 | -5.147 | -3.479 | -5.542 | -31.62 | -0.3641 | -0.9 | -3.6 | -3 | -2 |
| Net margin | - | -8.23% | -9.14% | -5.9% | -8.84% | -45.38% | -0.54% | -1.29% | -5.02% | -3.88% | -2.56% |
| EPS 2 | -9.750 | - | -0.1500 | -0.1500 | -0.1500 | -0.7500 | -0.0100 | -0.0200 | -0.0700 | -0.0600 | -0.0400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/22/22 | 3/2/23 | 5/15/23 | 8/9/23 | 11/9/23 | 3/28/24 | 5/8/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | 36 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 6/16/22 | 3/2/23 | 3/28/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7291
USD
Average target price
5
USD
Spread / Average Target
+585.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -73.41% | 35.88M | |
| +18.63% | 85.14B | |
| -27.41% | 72.06B | |
| +2.75% | 27.07B | |
| -9.66% | 17.43B | |
| -1.96% | 16.98B | |
| +3.96% | 16.02B | |
| +7.75% | 13.87B | |
| +72.83% | 13.06B | |
| +72.50% | 12.79B |
- Stock Market
- Equities
- NUTX Stock
- Financials Nutex Health Inc.
